Inspire Medical Systems develops and commercializes the Inspire therapy system, an implantable hypoglossal nerve stimulator for moderate to severe obstructive sleep apnea. The device is activated during sleep and offers an alternative for patients who cannot tolerate CPAP. Physicians implant and manage the system; the company focuses on training, clinical support, and direct sales in sleep medicine.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 201.3 | — | 3 | — |
| Q2 2025 | 217.1 | — | -3.6 | -137.1% |
| Q3 2025 | 224.5 | — | 9.9 | -44.5% |
| Q4 2025 | 269.1 | — | 136.1 | 294.9% |
| Q1 2026 | 204.6 | 1.6% | -11.3 | -477.5% |
| Q2 2026 | 200.6 | -7.6% | 0.3 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Worthington Steel, Inc. (WS), Douglas Emmett, Inc. (DEI), Insperity, Inc. (NSP), SmartStop Self Storage REIT, Inc. (SMA), Minerals Technologies Inc. (MTX), Applied Aerospace & Defense, Inc. (AADX)